A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Lebanon, New Hampshire 03756, United States
Charlotte, North Carolina 28277, United States
Wolloongabba, Queensland 4102, Australia
Shimotsuke-shi, Tochigi 3290498, Japan
Minato-ku, Tokyo 105-8471, Japan
Shinagawa-Ku, Tokyo 141-8625, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Skinjuku-ku, Tokyo 1690073, Japan
Wroc?aw, 51-318, Poland